Hepatocellular carcinoma on the background of nonalcoholic fatty liver disease: epidemiological update

Abstract

The epidemiological features of hepatocellular carcinoma have changed significantly in the last decades. While for a long-time viral hepatitis and alcohol consumption have been the leading risk factors, the current spread of obesity and type 2 diabetes has contributed to the emergence of non-alcoholic fatty liver disease (NAFLD) worldwide, which has become the leading chronic liver disease as well as one of the main etiologies of hepatocellular carcinoma (HCC), especially in western countries. In this review, we resume the latest data about the epidemiology of metabolic liver disease and HCC arising from NAFLD and discuss the main clinical and molecular features leading to the progression of liver disease and the development of HCC in NAFLD. The emerging concept of metabolic associated fatty liver disease and its association with the development of HCC are also introduced.

Keywords

Hepatocellular carcinoma / non-alcoholic fatty liver disease / metabolic associated fatty liver disease

References

[1] Younossi ZM,Abdelatif D,Henry L.Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes.Hepatology2016;64:73-84

[2] Arora SS,Ahmed Z.Decreasing frequency and improved outcomes of hepatitis C-related liver transplantation in the era of direct-acting antivirals - a retrospective cohort study.Transpl Int2019;32:854-64

[3] Younossi ZM,Younossi Y.Epidemiology of chronic liver diseases in the USA in the past three decades.Gut2020;69:564-8

[4] Mittal S,Sada YH.Hepatocellular carcinoma in the absence of cirrhosis in United States veterans is associated with nonalcoholic fatty liver disease.Clin Gastroenterol Hepatol2016;14:124-31.e1 PMCID:PMC4690789

[5] Yasui K,Komorizono Y.Japan NASH Study GroupMinistry of HealthLabourand Welfare of JapanCharacteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma.Clin Gastroenterol Hepatol2011;9:428-33; quiz e50

[6] Singh S,Wang Z,Murad MH.Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies.Clin Gastroenterol Hepatol2015;13:643-54.e1 PMCID:PMC4208976

[7] Pais R,Fedchuk L.LIDO Study GroupA systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver.J Hepatol2013;59:550-6

[8] Negro F.Natural history of NASH and HCC.Liver Int2020;40 Suppl 1:72-6

[9] Chalasani N,Lavine JE.The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American association for the study of liver diseases.Hepatology2018;67:328-57

[10] Brunt EM,Nobili V.Nonalcoholic fatty liver disease.Nat Rev Dis Primers2015;1:15080

[11] Spech HJ,Mitschke H.[Nonalcoholic fatty liver hepatitis and fatty cirrhosis mimicking alcoholic liver diseases].Z Gastroenterol1983;21:651-9

[12] Eslam M,Sarin SK.A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement.J Hepatol2020;73:202-9

[13] Piscaglia F,Barchetti A.HCC-NAFLD Italian Study GroupClinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: a multicenter prospective study.Hepatology2016;63:827-38

[14] Ajmera V,Wilson LA.Nonalcoholic Steatohepatitis Clinical Research NetworkAmong patients with nonalcoholic fatty liver disease, modest alcohol use is associated with less improvement in histologic steatosis and steatohepatitis.Clin Gastroenterol Hepatol2018;16:1511-20.e5 PMCID:PMC6098737

[15] Chang Y,Kim Y.Nonheavy drinking and worsening of noninvasive fibrosis markers in nonalcoholic fatty liver disease: a cohort study.Hepatology2019;69:64-75

[16] Younossi ZM.Epidemiology of non-alcoholic fatty liver disease and hepatocellular carcinoma.JHEP Rep2021;3:100305 PMCID:PMC8215299

[17] Cotter TG.Nonalcoholic fatty liver disease 2020: the state of the disease.Gastroenterology2020;158:1851-64

[18] Chooi YC,Magkos F.The epidemiology of obesity.Metabolism2019;92:6-10

[19] Khan MAB,King JK,Mustafa H.Epidemiology of type 2 diabetes - global burden of disease and forecasted trends.J Epidemiol Glob Health2020;10:107-11 PMCID:PMC7310804

[20] Perumpail BJ,Yoo ER,Kim D.Clinical epidemiology and disease burden of nonalcoholic fatty liver disease.World J Gastroenterol2017;23:8263-76 PMCID:PMC5743497

[21] Nabi O,Boursier J,Zins M.prevalence and risk factors of nonalcoholic fatty liver disease and advanced fibrosis in general population: the French nationwide NASH-CO study.Gastroenterology2020;159:791-3.e2

[22] Wong RJ,Cheung R.Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States.Gastroenterology2015;148:547-55

[23] Setiawan VW,Porcel J,Le Marchand L.Prevalence of chronic liver disease and cirrhosis by underlying cause in understudied ethnic groups: The multiethnic cohort.Hepatology2016;64:1969-77 PMCID:PMC5115980

[24] Farrell GC,Chitturi S.NAFLD in Asia--as common and important as in the West.Nat Rev Gastroenterol Hepatol2013;10:307-18

[25] Li J,Yeo YH.Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999–2019: a systematic review and meta-analysis.Lancet Gastroenterol Hepatol2019;4:389-98

[26] Estes C,Loomba R,Sanyal AJ.Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease.Hepatology2018;67:123-33 PMCID:PMC5767767

[27] Wong VW,Choi PC.Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years.Gut2010;59:969-74

[28] McPherson S,Henderson E,Day CP.Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management.J Hepatol2015;62:1148-55

[29] Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease.J Hepatol2016;64:1388-402

[30] Angulo P,Dam-Larsen S.Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease.Gastroenterology2015;149:389-97.e10 PMCID:PMC4516664

[31] Sanyal AJ,Clark J.NASH Clinical Research Network (CRN)Prospective study of outcomes in adults with nonalcoholic fatty liver disease.N Engl J Med2021;385:1559-69 PMCID:PMC8881985

[32] Vilar-Gomez E,Wai-Sun Wong V.fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease: a multi-national cohort study.Gastroenterology2018;155:443-57.e17

[33] Simon TG,Khalili H,Ludvigsson JF.Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort.Gut2021;70:1375-82 PMCID:PMC8185553

[34] Yatsuji S,Tobari M,Tokushige K.Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C.J Gastroenterol Hepatol2009;24:248-54

[35] Sanyal AJ,Sargeant C.Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C.Hepatology2006;43:682-9

[36] Valery PC,Clark PJ,McGlynn KA.Projections of primary liver cancer to 2030 in 30 countries worldwide.Hepatology2018;67:600-11 PMCID:PMC5832532

[37] Global hepatitis report, 2017 n.d. https://www.who.int/publications-detail-redirect/global-hepatitis-report-2017 [Last accessed on Mar 15, 2022]

[38] Wong RJ,Ahmed A.Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S.Hepatology2014;59:2188-95

[39] Dyson J,Chattopadyhay D.Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team.J Hepatol2014;60:110-7

[40] Association for the Study of the Liver. Electronic address: [e-mail]., European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma.J Hepatol2018;69:182-236

[41] Anstee QM,Kotsiliti E,Heikenwalder M.From NASH to HCC: current concepts and future challenges.Nat Rev Gastroenterol Hepatol2019;16:411-28

[42] Allaire M,Nahon P,Nault JC.Hepatocellular carcinoma: the Impact of NAFLD.Curr Hepatology Rep2016;15:190-8

[43] Tobari M,Taniai M.The characteristics and risk factors of hepatocellular carcinoma in nonalcoholic fatty liver disease without cirrhosis.J Gastroenterol Hepatol2020;35:862-9

[44] Younossi ZM,Henry L.Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009.Hepatology2015;62:1723-30

[45] Than NN,Hodson J.Comparing clinical presentations, treatments and outcomes of hepatocellular carcinoma due to hepatitis C and non-alcoholic fatty liver disease.QJM2017;110:73-81 PMCID:PMC5444673

[46] Golabi P,Henry L.Hepatocellular carcinoma and non-alcoholic fatty liver disease.Hepatol Int2019;13:688-94

[47] Myers S,Spahr L.NAFLD and MAFLD as emerging causes of HCC: A populational study.JHEP Rep2021;3:100231 PMCID:PMC7957147

[48] Lin S,Wang M.Comparison of MAFLD and NAFLD diagnostic criteria in real world.Liver Int2020;40:2082-9

[49] Estes C,Arias-Loste MT.Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030.J Hepatol2018;69:896-904

[50] Eslam M,Romeo S.Genetics and epigenetics of NAFLD and NASH: clinical impact.J Hepatol2018;68:268-79

[51] Browning MG,DeAntonio JH.Protective effect of black relative to white race against non-alcoholic fatty liver disease in patients with severe obesity, independent of type 2 diabetes.Int J Obes (Lond)2018;42:926-9

[52] Romeo S,Xing C.Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease.Nat Genet2008;40:1461-5 PMCID:PMC2597056

[53] Pan JJ.Gender and racial differences in nonalcoholic fatty liver disease.World J Hepatol2014;6:274-83 PMCID:PMC4033285

[54] Dongiovanni P,Valenti L.Genetic predisposition in NAFLD and NASH: impact on severity of liver disease and response to treatment.Curr Pharm Des2013;19:5219-38 PMCID:PMC3850262

[55] BasuRay S,Smagris E,Hobbs HH.Accumulation of PNPLA3 on lipid droplets is the basis of associated hepatic steatosis.Proc Natl Acad Sci U S A2019;116:9521-6 PMCID:PMC6511016

[56] Falleti E,Cmet S.PNPLA3 rs738409C/G polymorphism in cirrhosis: relationship with the aetiology of liver disease and hepatocellular carcinoma occurrence.Liver Int2011;31:1137-43

[57] Liu YL,Leathart JB.Carriage of the PNPLA3 rs738409 C > G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma.J Hepatol2014;61:75-81

[58] Seko Y,Tanaka S.Development of hepatocellular carcinoma in Japanese patients with biopsy-proven non-alcoholic fatty liver disease: Association between PNPLA3 genotype and hepatocarcinogenesis/fibrosis progression.Hepatol Res2017;47:1083-92

[59] Kozlitina J,Stender S.Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease.Nat Genet2014;46:352-6 PMCID:PMC3969786

[60] Liu YL,Burt AD.TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease.Nat Commun2014;5:4309 PMCID:PMC4279183

[61] Yang J,Nahon P.PNPLA3 and TM6SF2 variants as risk factors of hepatocellular carcinoma across various etiologies and severity of underlying liver diseases.Int J Cancer2019;144:533-44

[62] Nahon P,Nault JC.Characterizing the mechanism behind the progression of NAFLD to hepatocellular carcinoma.Hepat Oncol2020;7:HEP36 PMCID:PMC7907968

[63] Campani C.Molecular mechanisms of liver carcinogenesis related to metabolic syndrome.HR2022;

[64] Tanaka Y,Caddeo A.LPIAT1/MBOAT7 depletion increases triglyceride synthesis fueled by high phosphatidylinositol turnover.Gut2021;70:180-93 PMCID:PMC7788230

[65] Motomura T,Diaz-Aragon R.Is HSD17B13 genetic variant a protector for liver dysfunction?.J Pers Med2021;11:619 PMCID:PMC8304981

[66] Pinyol R,Wang H.Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis.J Hepatol2021;75:865-78

[67] Kuramoto J,Tian Y.Genome-wide DNA methylation analysis during non-alcoholic steatohepatitis-related multistage hepatocarcinogenesis: comparison with hepatitis virus-related carcinogenesis.Carcinogenesis2017;38:261-70 PMCID:PMC5862314

[68] de Conti A,Tryndyak V.Inhibition of the cell death pathway in Nonalcoholic Steatohepatitis (NASH)-related hepatocarcinogenesis is associated with histone H4 lysine 16 deacetylation.Mol Cancer Res2017;15:1163-72

[69] Wong CM,Ng IO.Non-coding RNAs in hepatocellular carcinoma: molecular functions and pathological implications.Nat Rev Gastroenterol Hepatol2018;15:137-51

[70] Gellert-Kristensen H,Davey Smith G,Tybjaerg-Hansen A.Combined effect of PNPLA3, TM6SF2, and HSD17B13 variants on risk of cirrhosis and hepatocellular carcinoma in the general population.Hepatology2020;72:845-56

[71] Bianco C,Pelusi S.Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores.J Hepatol2021;74:775-82 PMCID:PMC7987554

[72] Poeta M,Vajro P.Gut-liver axis derangement in non-alcoholic fatty Liver disease.Children (Basel)2017;4:66 PMCID:PMC5575588

[73] Qin N,Li A.Alterations of the human gut microbiome in liver cirrhosis.Nature2014;513:59-64

[74] Milosevic I,Barac A.Gut-Liver Axis, Gut Microbiota, and Its Modulation in the Management of Liver Diseases: A Review of the Literature.Int J Mol Sci2019;20:395 PMCID:PMC6358912

[75] Tripathi A,Brenner DA.The gut-liver axis and the intersection with the microbiome.Nat Rev Gastroenterol Hepatol2018;15:397-411 PMCID:PMC6319369

[76] Dong TS,Lagishetty V.Gut microbiome profiles associated with steatosis severity in metabolic associated fatty liver disease.HR2021;

[77] Cani PD,Iglesias MA.Metabolic endotoxemia initiates obesity and insulin resistance.Diabetes2007;56:1761-72

[78] Verdam FJ,Driessen A,Buurman WA.Novel evidence for chronic exposure to endotoxin in human nonalcoholic steatohepatitis.J Clin Gastroenterol2011;45:149-52

[79] Sinal CJ,Miyata M,Lambert G.Targeted disruption of the nuclear receptor fxr/bar impairs bile acid and lipid homeostasis.Cell2000;102:731-44

[80] Ponziani FR,Castelli C.Hepatocellular carcinoma is associated with gut microbiota profile and inflammation in nonalcoholic fatty liver disease.Hepatology2019;69:107-20

[81] Schwabe RF.Gut microbiome in HCC - mechanisms, diagnosis and therapy.J Hepatol2020;72:230-8

[82] Zhang X,Chu ES.Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites.Gut2021;70:761-74 PMCID:PMC7948195

[83] Castera L,Loomba R.Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease.Gastroenterology2019;156:1264-81.e4 PMCID:PMC7505052

[84] Wong VW,Chitturi S.Asia-Pacific working party on non-alcoholic fatty liver disease guidelines 2017-part 1: definition, risk factors and assessment.J Gastroenterol Hepatol2018;33:70-85

[85] Loomba R,Patton H.AGA clinical practice update on screening and surveillance for hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: expert review.Gastroenterology2020;158:1822-30 PMCID:PMC8012107

[86] Simmons O,Yokoo T.Predictors of adequate ultrasound quality for hepatocellular carcinoma surveillance in patients with cirrhosis.Aliment Pharmacol Ther2017;45:169-77 PMCID:PMC7207219

[87] Park HJ,Kim SY.Non-enhanced magnetic resonance imaging as a surveillance tool for hepatocellular carcinoma: comparison with ultrasound.J Hepatol2020;72:718-24